Corona Remedies IPO received an overwhelming investor interest, achieving an overall oversubscription of 137 times, driven largely by strong participation from QIBs
The ₹10,602.65-crore IPO is a pure Offer for Sale (OFS), with Prudential Corporation Holdings offloading up to 49 million (48,972,994) equity shares, as detailed in the Red Herring Prospectus (RHP)
Once the allotment is finalised, investors who applied for Corona Remedies IPO can check their status on the official websites of BSE, NSE, or Bigshare Services, the registrar for the issue
The listing closely mirrored activity in the grey market, where the company's shares were quoted around ₹154 each, indicating a premium of ₹43, or 38.74 per cent over the issue price
Nephrocare Health IPO comprises a fresh issue of 7.7 million, amounting to ₹353.4 crore and an offer for sale (OFS) of 11.3 million equity shares amounting to ₹517.64 crore
Ahead of its listing, the unlisted shares of Aequs were trading at around ₹152 per share in the grey market, indicating a premium of ₹28 or 22.6 per cent
The unlisted shares of Park Medi World were trading at ₹193 in the grey market, commanding a premium of ₹33 or 20 per cent from the upper end price of ₹162
Once the allotment is finalised, investors who applied for the public offering can check their status on the official websites of BSE, NSE, or Kfin Technologies, the registrar for the issue